Information Provided By:
Fly News Breaks for April 26, 2016
SRPT
Apr 26, 2016 | 07:30 EDT
Jefferies analyst Gena Wang lowered her price target for Sarepta Therapeutics to $7 saying the FDA panelists voting negative on eteplirsen efficacy was in-line with her thesis. The outcome suggests the worst scenario for Sarepta, with likely a new Phase 3 study required for full approval, Wang tells investors in a research note. The analyst keeps a Hold rating on the shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.